Navigation Links
XTL Announces Delisting From the Official List of the United Kingdom Listing Authority
Date:10/31/2007

Processing Fees on Transfer of Ordinary Shares Into ADRs to be Waived for

an Additional Month

VALLEY COTTAGE, New York, October 31 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTL) today announced that the Company's ordinary shares have been delisted from the Official List of the United Kingdom Listing Authority, pursuant to the October 2, 2007 vote at the Company's Extraordinary General Meeting. With the cancellation of the listing on the London Stock Exchange, shareholders may deposit their ordinary shares with the Company's depositary bank, The Bank of New York, in exchange for American Depositary Receipts, or ADRs, which are traded on NASDAQ, or trade their ordinary shares on the TASE.

XTL Biopharmaceuticals Ltd. has further announced that issuances of ADRs by The Bank of New York will be processed free of the customary charges of The Bank of New York for an additional month, through November 30, 2007. The Bank of New York will issue ADRs representing American Depositary Shares, or ADSs, if shareholders or their broker deposit Ordinary Shares with The Bank of New York's Custodian, either the Tel Aviv office of Bank Hapoalim B.M., or the London office of The Bank of New York. One ADR will represent an ownership interest in ten of the Company's Ordinary Shares.

Interested investors should contact their brokers to discuss the waived fee and, should they have any questions, can contact The Bank of New York in either London or New York as follows:

London:

Mark Lewis,

Vice President,

Tel +44(0)20-7964-6089,

Fax +44(0)20-7964-6024,

marlewis@bankofny.com

New York:

Jason Paltrowitz,

Vice President,

Tel +1-212-815-2077,

Fax +1-212-815-3004,

jpaltrowitz@bankofny.com

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; TASE: XTL).

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating continued undisrupted trading of the Company's ADRs on NASDAQ and similar matters, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Risk factors that could adversely affect our operations are identified from time to time in our reports filed with the Securities and Exchange Commission, including our annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2007. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.xtlbio.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only. This press release is for informational purposes only and is not an offer to by or the solicitation of an offer to sell any securities.

Contact:

Ron Bentsur,

Chief Executive Officer

Tel: +1-845-267-0707 ext. 225


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its ... Life" or "Wonder Spice", it has been used for thousands of years. , "The ... says Heshelow, author of " Turmeric: How to Use it For Your Wellness. Overcome ...
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs sold 300 ... Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these results while ... HeartBoost, an over the counter heart healthy drink, can reduce Arterial Plaque, Lower ...
(Date:3/29/2017)... OK (PRWEB) , ... March 29, 2017 , ... ... now receive FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with ... straighten teeth efficiently, compared to traditional orthodontic treatment. Depending on each patient’s case, ...
(Date:3/29/2017)... ... March 29, 2017 , ... How big ... outpatient facilities, and who are the most active developers? , In the ... Healthcare Real Estate Insights (HREI) found that outpatient medical real estate development projects ...
(Date:3/29/2017)... ... 2017 , ... An inventor from Raynham, Mass., knows the ... conjunction with my braces always rubbed against the inside of my cheeks, causing ... problem." The O.B.S. was the result of his brainstorming. , This patent-pending invention ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017 Avelas Biosciences, Inc., a clinical ... through treatment, today announced that Carmine N. Stengone , president ... at the Needham & Company 16 th Annual Healthcare Conference ... PDT) at the Westin Grand Central Hotel in New ... ...
(Date:3/29/2017)... EAST HANOVER, N.J. , March 29, 2017 ... and Drug Administration (FDA) has accepted the company,s ... review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen ... refractory (r/r) pediatric and young adult patients with ... first BLA submission by Novartis for a CAR-T. ...
(Date:3/29/2017)... March 29, 2017 Today, CVS Health officials (NYSE: ... Reynolds , Department of Public Health Director Gerd Clabaugh ... Lukan in announcing the availability of the opioid overdose-reversal ... in Iowa.  CVS Health has established a standing order with ... Pharmacy to expand access to the medication in the state.   ...
Breaking Medicine Technology: